April 05, 2022
2 min watch
Save
VIDEO: De-escalation strategies for HER2-positive breast cancer treatment side effects
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Sara Hurvitz, MD, discussed her presentation at 39th Miami Breast Cancer Conference.on strategies and tactics clinicians can use to de-escalate side effects for patients being treated for HER2-positive breast cancer.
The de-escalation strategies Hurvitz, an associate professor at David Geffen School of Medicine at UCLA and medical director of Jonsson Comprehensive Cancer Center Clinical Research Unit, discussed included removing certain chemotherapy drugs such as anthracyclines from the armamentarium.
In addition, she reviewed how to decide when a patient is a good candidate for treatment with adjuvant pertuzumab or neratinib vs. T-DM1.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Disclosures: Hurvitz reports contracted research/preclinical work paid to institution by Ambrx, Amgen, Arvinas, Astra Zeneca, Bayer, CytomX, Daiichi-Sankyo, Dignitana, Eli Lilly, Genentech/Roche, Gilead, GlaxoSmithKline, Immunomedics, Macrogenics, Novartis, Pfizer, Phoenix Molecular Designs, OBI Pharma, Orinove, Pieris, PUMA, Radius, Samumed, Sanofi, Seagen and Zymeworks; national/international PI from Daiichi-Sankyo, Genentech/Roche, Novartis and Seagen; serving on a steering committee for Daiichi-Sankyo/AstraZeneca, Eli Lilly, Genentech/Roche, Novartis and Sanofi; travel expenses from Eli Lilly (2019); and uncompensated ad boards and/or consulting for 4DPharma, Ambrx, Amgen, Artios, Arvinas, Biotheranostics, Daiichi Sankyo, Dantari, Eli Lilly, Genentech/Roche, Immunomedics, Macrogenics, Novartis, NK Max, Pieris, Pyxis and Seagen.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.